News & Event
- Home
- News
- News & Event
PharmaResearch to build its 5th factory in Gangneung with KRW 100 bn investment
Biopharmaceutical company PharmaResearch will invest over KRW 100 billion to establish its 5th factory in Gangneung.
On December 10th, Gangwon State and Gangneung City signed a memorandum of understanding (MOU) with PharmaResearch for the construction of the Gangneung 5th factory.
Under the investment agreement, PharmaResearch plans to invest a total of KRW 100.2 billion to build a factory with a total floor area of 25,073.3 square meters on a 30,756㎡ site in Bangdong-ri, Sacheon-myeon, Gangneung, within the Gangneung Science and Industry Complex. The factory is expected to be completed by 2027.
In addition, more than 50 new employees will be hired.
Gangwon State and Gangneung-si will actively provide administrative services, such as permits and business support, and collaborate to ensure the early and smooth operation of the 5th factory.
This investment by PharmaResearch is expected to strengthen the production base for regenerative medicine and aesthetics in the Gangneung region, expand the bio-industry ecosystem in the province, and significantly contribute to the revitalization of the local economy.
Notably, the provincial government and Gangneung-si have been selected for the 'Regional Anchor Company and Regional University Strategic Technology Joint Development Project' competition, hosted by the Ministry of Trade, Industry, and Resources (MOTIR) and the Ministry of Education (MOE). They are currently working on a project to commercialize medical products for treating oral diseases, involving local universities and companies, in collaboration with PharmaResearch.
As part of this, the provincial government and Gangneung-si plan to develop medical materials for alveolar bone and soft tissue regeneration with PharmaResearch by 2029.
Meanwhile, PharmaResearch has been expanding its diverse product portfolio, including pharmaceuticals, aesthetic medical devices, and dermacosmetics, based on its patented technology in regenerative medicine. The company, particularly with its brand REJURAN, has achieved high growth with an average annual sales growth rate of 30%.
yoo21@yna.co.kr
Source Text
** This article was translated from Korean.
Date
2025.12.16
Views
23
According to Yonhap News,
Biopharmaceutical company PharmaResearch will invest over KRW 100 billion to establish its 5th factory in Gangneung.
On December 10th, Gangwon State and Gangneung City signed a memorandum of understanding (MOU) with PharmaResearch for the construction of the Gangneung 5th factory.
Under the investment agreement, PharmaResearch plans to invest a total of KRW 100.2 billion to build a factory with a total floor area of 25,073.3 square meters on a 30,756㎡ site in Bangdong-ri, Sacheon-myeon, Gangneung, within the Gangneung Science and Industry Complex. The factory is expected to be completed by 2027.
In addition, more than 50 new employees will be hired.
Gangwon State and Gangneung-si will actively provide administrative services, such as permits and business support, and collaborate to ensure the early and smooth operation of the 5th factory.
This investment by PharmaResearch is expected to strengthen the production base for regenerative medicine and aesthetics in the Gangneung region, expand the bio-industry ecosystem in the province, and significantly contribute to the revitalization of the local economy.
Notably, the provincial government and Gangneung-si have been selected for the 'Regional Anchor Company and Regional University Strategic Technology Joint Development Project' competition, hosted by the Ministry of Trade, Industry, and Resources (MOTIR) and the Ministry of Education (MOE). They are currently working on a project to commercialize medical products for treating oral diseases, involving local universities and companies, in collaboration with PharmaResearch.
As part of this, the provincial government and Gangneung-si plan to develop medical materials for alveolar bone and soft tissue regeneration with PharmaResearch by 2029.
Meanwhile, PharmaResearch has been expanding its diverse product portfolio, including pharmaceuticals, aesthetic medical devices, and dermacosmetics, based on its patented technology in regenerative medicine. The company, particularly with its brand REJURAN, has achieved high growth with an average annual sales growth rate of 30%.
yoo21@yna.co.kr
Source Text
Copyrights Yonhap News. All Rights Reserved.
Reprint or redistribution without permission is prohibited.
Source: Yonhap News (December 10, 2025)
** This article was translated from Korean.